Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Sileny N HanFrédéric Amant

Abstract

To evaluate efficacy of weekly paclitaxel/carboplatin chemotherapy in patients with locally advanced, metastatic, or recurrent vulvar squamous cell carcinoma. A prospective, single-arm, single-center pilot study was initiated to study response rate of 9 weekly courses of paclitaxel (60 mg/m) and carboplatin (area under the curve, 2.7). We used this regimen in the neoadjuvant or metastatic setting when surgery would cause serious morbidity or was not an option owing to distant metastases. Primary outcome was response rate, measured according to Response Criteria in Solid Tumors criteria. Treatment toxicity, surgical morbidity, and type of surgery were also evaluated. We treated 6 patients in the period between May 2009 and May 2011, of which 4 patients had a diagnosis of locally advanced disease and 2 patients had a diagnosis of recurrent disease. A median number of 7.5 cycles of paclitaxel/carboplatin weekly was administered (range, 3-9). No objective response was observed. Paclitaxel/carboplatin weekly was discontinued after a mean of 4.3 weekly cycles in 3 patients owing to local disease progression. After a median follow-up of 4.2 months (range, 1-29 months), 3 patients died owing to progressive disease and 1 patient died ow...Continue Reading

References

Dec 20, 2005·Best Practice & Research. Clinical Obstetrics & Gynaecology·R Sankaranarayanan, J Ferlay
Mar 24, 2007·International Journal of Clinical Oncology·Angeles Alvarez SecordAndrew Berchuck
May 15, 2007·Gynecologic Oncology·Isabelle CadronIgnace Vergote
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 17, 2009·Current Oncology·O G ScharovskyV R Rozados
Oct 13, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ingrid VandenputFrédéric Amant
Feb 23, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ana Patrícia DominguesCarlos Freire de Oliveira
Jul 8, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Linn WoelberSven Mahner

❮ Previous
Next ❯

Citations

Oct 16, 2013·Current Oncology Reports·Kathryn Graham, Kevin Burton
Mar 23, 2013·Wiener klinische Wochenschrift·Gunter DeppeIra S Winer
Jul 13, 2016·Gynecologic Oncology·Katharina PrieskeLinn Woelber
Nov 22, 2017·International Journal of Clinical Oncology·Toshiaki SaitoHidetaka Katabuchi
Jan 25, 2014·Journal of Gynecologic Oncology·Francesco RaspagliesiAntonino Ditto
Mar 19, 2015·The American Journal of Surgical Pathology·Emily R HolthoffSteven R Post
May 23, 2015·Expert Review of Anticancer Therapy·Sven MahnerLinn Woelber
Jul 6, 2020·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Jo MorrisonChristina Fotopoulou
Aug 28, 2021·Cancers·Marco MazzottaPatrizia Vici

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.